⌕
Xenon Pharmaceuticals · XENE · Nasdaq
Tenet 44 · Weak
Compare
$38.78−1.22%At closeTenet 44 · Weak
$38.78−0.48 (−1.22%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Xenon Pharmaceuticals (XENE) Institutional Ownership

13F filers reported holding 51.1% of Xenon Pharmaceuticals (XENE) shares as of Sep 30, 2026, across 197 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
51.1%
Sep 30, 2026
13F filers
197
quarter ended Sep 30, 2026
13F value
$1.9B
50.2M shares
Quarter's fund flow
Mild accumulation
23 new · 30 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (23 new · 96 increased · 54 reduced · 30 closed). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 197 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Oct 15, 2026Kelly Thomas PatrickChief Financial OfficerAcquired · Option exercise7,500Common Shares—↗
Oct 15, 2026Kelly Thomas PatrickChief Financial OfficerDisposed · Option exercise7,500Restricted Share Units—↗
Sep 30, 2026Kelly Thomas PatrickChief Financial OfficerAcquired · Open-market buy15,000Common Shares$37.32↗
Sep 30, 2026MORTIMER IANPRESIDENT & CEOAcquired · Open-market buy30,000Common Shares$37.38↗
Sep 1, 2026Svoronos DawndirectorAcquired · Option exercise5,144Common Shares$8.15↗
Sep 1, 2026Svoronos DawndirectorDisposed · Option exercise5,144Stock Option (Right to Buy)—↗
Aug 28, 2026KENNEY CHRISTOPHER JOHNChief Medical OfficerDisposed · Open-market sale6,368Common Shares$60.17↗
Aug 28, 2026KENNEY CHRISTOPHER JOHNChief Medical OfficerDisposed · Open-market sale700Common Shares$60.98↗
Aug 11, 2026GANNON STEVENdirectorDisposed · Open-market sale10,000Common Shares$64.06↗
Jun 5, 2026PATOU GARYdirectorDisposed · Open-market sale1,322Common Shares$53.14↗
Jun 5, 2026Cannon GilliandirectorDisposed · Open-market sale1,190Common Shares$53.14↗
Jun 3, 2026PATOU GARYdirectorAcquired · Grant / award10,507Share Option (Right to Buy)—↗
Jun 3, 2026PATOU GARYdirectorAcquired · Grant / award1,593Restricted Share Units—↗
Jun 3, 2026Machado PatrickdirectorAcquired · Grant / award10,507Share Option (Right to Buy)—↗
Jun 3, 2026Machado PatrickdirectorAcquired · Grant / award1,593Restricted Share Units—↗
Jun 3, 2026Gover Justin D.directorAcquired · Grant / award10,507Share Option (Right to Buy)—↗
Jun 3, 2026Gover Justin D.directorAcquired · Grant / award1,593Restricted Share Units—↗
Jun 3, 2026GAROFALO ELIZABETH A.directorAcquired · Grant / award10,507Share Option (Right to Buy)—↗
Jun 3, 2026GAROFALO ELIZABETH A.directorAcquired · Grant / award1,593Restricted Share Units—↗
Jun 3, 2026GANNON STEVENdirectorAcquired · Grant / award10,507Share Option (Right to Buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Xenon Pharmaceuticals do institutions hold?

13F filers reported holding 51.1% of Xenon Pharmaceuticals' shares as of Sep 30, 2026, across 197 filers.

How many 13F filers hold Xenon Pharmaceuticals?

Xenon Pharmaceuticals was held by 197 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.